Related Experiment Video

Updated: Jun 9, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Diagnosis and management of giant cell arteritis: a review

Nilufer Kale1, Eric Eggenberger

  • 1Department of Neuro-Ophthalmology, Michigan State University, Michigan, USA.

Current Opinion in Ophthalmology
|September 3, 2010
PubMed

Insights

Giant cell arteritis (GCA) is a vasculitis affecting large arteries, presenting with headache and visual loss. Diagnosis involves temporal artery biopsy, blood tests, and imaging, with corticosteroids as primary treatment.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic immune-mediated vasculitis impacting medium and large arteries.
  • Characterized by symptoms like headache, jaw claudication, and visual disturbances, GCA results from vascular insufficiency and tissue ischemia.

Purpose of the Study:

  • To review the clinical features of GCA.
  • To discuss differential diagnosis, current treatment strategies, and recent literature.
  • To highlight the importance of early diagnosis and management to prevent vision loss.

Main Methods:

  • Literature review of GCA clinical features, diagnosis, and treatment.
  • Discussion of diagnostic modalities including temporal artery biopsy (TAB), blood tests (ESR, CRP), and imaging (ultrasound, MRI, PET).
  • Overview of management approaches, including corticosteroids and steroid-sparing agents.

Main Results:

  • GCA presents with characteristic symptoms and requires prompt diagnosis.
  • Temporal artery biopsy (TAB) is the gold standard, supported by laboratory tests and advanced imaging.
  • Current treatment focuses on high-dose corticosteroids, with adjunctive therapies considered.

Conclusions:

  • Further research into GCA immunogenetics is essential.
  • Development of more sensitive diagnostic tests and novel corticosteroid-sparing treatments is needed.
  • Continued investigation into GCA pathogenesis and treatment optimization is crucial.
Abstract

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...